Compare MLGO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | BTAI |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 35.6M |
| IPO Year | 2020 | 2018 |
| Metric | MLGO | BTAI |
|---|---|---|
| Price | $3.72 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.33 |
| AVG Volume (30 Days) | 122.4K | ★ 818.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,132,230.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | $0.91 | ★ N/A |
| Revenue Growth | ★ 6.21 | N/A |
| 52 Week Low | $0.50 | $1.17 |
| 52 Week High | $32.40 | $8.08 |
| Indicator | MLGO | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 40.90 |
| Support Level | $0.53 | $1.50 |
| Resistance Level | $4.83 | $2.28 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 47.96 | 8.57 |
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.